Sun Pharma Advanced Research Company (SPARC) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2024.

• Approved incorporation of a wholly-owned subsidiary to support R&D and related services.

Financial highlights

• Q3 FY25 consolidated revenue from operations: ₹1,491 lakhs, down from ₹1,386 lakhs in Q3 FY24.

• Q3 FY25 consolidated net loss: ₹7,951 lakhs, compared to net loss of ₹9,965 lakhs in Q3 FY24.

• Nine months FY25 consolidated revenue: ₹4,458 lakhs, down from ₹5,899 lakhs in the prior year period.

• Nine months FY25 consolidated net loss: ₹28,274 lakhs, compared to net loss of ₹28,142 lakhs year-over-year.

• Standalone and consolidated results both reflect continued operating losses and negative EPS.

Outlook and guidance

• Status as a going concern is maintained based on a support letter from the promoter group.

• Closure of the Parkinson Disease program (K0706) following PROSEEK trial results; provision of ₹1,100 lakhs made for project closure costs.